THERAPY DOSSIER · th-da32f4908c54

Lecithinized superoxide dismutase (PC-SOD)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03995732 ↗Injury indicationPHASE2unknown

Efficacy and Safety Evaluation of Phosphatidyl Choline Cu/Zn Superoxide Dismutase (PC-SOD) for Injection in Reducing Myocardial Reperfusion Injury

Myocardial Reperfusion Injury

Enrolment: 120 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27668315 ↗2017Reported benefit

Evaluation of Lecithinized Superoxide Dismutase for the Prevention of Acute Respiratory Distress Syndrome in Animal Models.

MouseEndotoxin/LPSICRMaleIntravenousFirst dose given just before caecal ligation and puncture

Model: Three models of acute respiratory distress syndrome and ventilator-induced lung injury: caecal ligation and puncture, lipopolysaccharide administration, and mechanical ventilation

Intravenous PC-SOD increased survival and decreased vascular permeability after caecal ligation and puncture, and suppressed vascular permeability, oedema, tissue injury and inflammation after LPS and after mechanical ventilation. Unlike dexamethasone and sivelestat, PC-SOD also suppressed kidney i…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…